BioCentury
ARTICLE | Company News

Qiagen, Merck infectious news

May 2, 2011 7:00 AM UTC

Merck and Qiagen will provide HPV vaccination and screening in Rwanda under the partners' cervical cancer prevention program initiated in 2009. Merck will provide more than 2 million doses of its Gardasil HPV vaccine to girls ages 12-15 and Qiagen will provide 250,000 HPV screening tests to women ages 35-45 at no cost for three years. After three years, Merck will provide its vaccine at a discounted price, and Qiagen will provide its tests under a tiered market pricing structure that enables developing countries to receive a reduced rate. Qiagen's tests include its digene HC2 HPV DNA cervical cancer screening test and its portable careHPV test (see BioCentury, Sept. 28, 2009). ...